CO5570701A2 - Activadores de ppar - Google Patents
Activadores de pparInfo
- Publication number
- CO5570701A2 CO5570701A2 CO05048657A CO05048657A CO5570701A2 CO 5570701 A2 CO5570701 A2 CO 5570701A2 CO 05048657 A CO05048657 A CO 05048657A CO 05048657 A CO05048657 A CO 05048657A CO 5570701 A2 CO5570701 A2 CO 5570701A2
- Authority
- CO
- Colombia
- Prior art keywords
- carbon
- optionally
- alkyl
- independently
- isomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
1.- Un compuesto de Fórmula I un isómero del mismo, un profármaco de dicho compuesto o isómero, o una sal farmacéuticamente aceptable de dicho compuesto, isómero o profármaco;en el que m y n son, cada uno independientemente, uno o dos;V e Y son, cada uno independientemente, a) metileno, o b) carbonilo;F y G son, cada uno independientemente, a) hidrógeno, b) halo, c) alquilo (C1-C4) sustituido opcionalmente con de uno a nueve átomos de flúor, d) cicloalquilo (C3-C6); e) hidroxi, f) alcoxi (C1-C4) o g) alquiltio (C1-C4);X es a) -Z o b) -B-C(R1R2)-Z;B es a) oxi, b) tio, c) sulfinilo,d) sulfonilo, e) metileno, o f) -N(H)-;Z es a) -C(O)OH, b) -C(O)O-alquilo (C1-C4), c) -C(O)O-alquil (C0-C4)arilo, d) -C(O)-NH2, e) hidroxiaminocarbonilo, f) tetrazolilo, g) tetrazolilaminocarbonilo, h) 4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-ilo, i) 3-oxoisoxazolidin-4-il-aminocarbonilo, j) -C(O)N(H)SO2R4, o k) -NHSO2R4; en el que R4 es a) alquilo (C1-C6), b) amino o c) mono-N o di-N,N-alquil (C1-C6) amino, estando los sustituyentes alquilo (C1-C6) en R4 opcionalmente e independientemente sustituidos con de uno a nueve átomos de flúor;R1 es a) H, b) alquilo (C1-C4) o c) cicloalquilo (C3-C6);R2 es a) H, b) cicloalquilo (C3-C6) o c) una cadena de carbono de uno a cuatro miembros, lineal o ramificada, total o parcialmente saturada o totalmente insaturada; en la que el(los) carbono(s) de la cadena de carbono pueden reemplazarse con uno o dos heteroátomos seleccionados independientemente entre oxígeno y azufre; y en la que el azufre está opcionalmente mono o disustituido con oxo;en la que el(los) carbono(s) de la cadena de carbono de R2 están opcionalmente sustituidos independientemente como sigue: a) el(los) carbono(s) están opcionalmente mono, di o trisustituidos independientemente con halo, b) el(los) carbono(s) están opcionalmente monosustituidos con hidroxi o alcoxi (C1-C4), y c) el (los) carbono(s) están opcionalmente monosustituidos con oxo; y en la que el(los) carbono(s) de la cadena de carbono de R2 están opcionalmente monosustituidos con Q;en la que Q es un anillo de tres a ocho miembros, parcial o totalmente saturado o totalmente insaturado, que tiene, opcionalmente, de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42950602P | 2002-11-26 | 2002-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570701A2 true CO5570701A2 (es) | 2005-10-31 |
Family
ID=32393563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05048657A CO5570701A2 (es) | 2002-11-26 | 2005-05-19 | Activadores de ppar |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7199243B2 (es) |
| EP (1) | EP1567493B1 (es) |
| JP (1) | JP4029091B2 (es) |
| KR (2) | KR100875318B1 (es) |
| CN (1) | CN100439337C (es) |
| AR (1) | AR042131A1 (es) |
| AT (1) | ATE425966T1 (es) |
| AU (1) | AU2003276596B8 (es) |
| BR (1) | BR0316521A (es) |
| CA (1) | CA2507465C (es) |
| CO (1) | CO5570701A2 (es) |
| DE (1) | DE60326752D1 (es) |
| DK (1) | DK1567493T3 (es) |
| EA (1) | EA008928B1 (es) |
| ES (1) | ES2321509T3 (es) |
| GT (1) | GT200300258A (es) |
| HK (1) | HK1083502A1 (es) |
| HR (1) | HRP20050437A2 (es) |
| IS (1) | IS7816A (es) |
| MA (1) | MA27532A1 (es) |
| MX (1) | MXPA05005583A (es) |
| NL (1) | NL1024881C2 (es) |
| NO (1) | NO20052921L (es) |
| NZ (1) | NZ539546A (es) |
| PE (1) | PE20040699A1 (es) |
| PL (1) | PL378268A1 (es) |
| PT (1) | PT1567493E (es) |
| SI (1) | SI1567493T1 (es) |
| TN (1) | TNSN05146A1 (es) |
| TW (1) | TW200424172A (es) |
| UA (1) | UA83202C2 (es) |
| UY (1) | UY28097A1 (es) |
| WO (1) | WO2004048334A1 (es) |
| ZA (1) | ZA200503104B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048334A1 (en) * | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Phenyl substituted piperidine compounds for use as ppar activators |
| MXPA06013674A (es) * | 2004-05-25 | 2007-02-13 | Pfizer Prod Inc | Nuevo uso. |
| BRPI0511481A (pt) * | 2004-05-25 | 2007-12-26 | Pfizer Prod Inc | uso |
| MX2007001634A (es) | 2004-08-11 | 2007-04-23 | Kyorin Seiyaku Kk | Nuevo derivado de acido amino benzoico ciclico. |
| AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
| WO2006101108A1 (ja) * | 2005-03-23 | 2006-09-28 | Kyorin Pharmaceutical Co., Ltd. | 新規環状アミノフェニルアルカン酸誘導体 |
| GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| US8097610B2 (en) * | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
| WO2007120605A2 (en) * | 2006-04-11 | 2007-10-25 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists |
| JP2010511038A (ja) * | 2006-12-01 | 2010-04-08 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体阻害剤としての３−ヘテロアリール（アミノ又はアミド）−１−（ビフェニル又はフェニルチアゾリル）カルボニルピペリジン誘導体 |
| WO2009011872A1 (en) | 2007-07-17 | 2009-01-22 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| PT2178865E (pt) * | 2007-07-19 | 2015-11-16 | Lundbeck & Co As H | Amidas heterocíclicas com 5 membros e compostos relacionados |
| TW201006816A (en) | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| FR2935510B1 (fr) | 2008-08-28 | 2010-12-10 | Oberthur Technologies | Procede d'echange de donnees entre deux entites electroniques |
| FR2935511B1 (fr) | 2008-08-28 | 2010-12-10 | Oberthur Technologies | Procede d'echange de donnees entre deux entites electroniques |
| UA107938C2 (en) * | 2009-08-12 | 2015-03-10 | Syngenta Participations Ag | Heterocycles with microbicidal properties |
| EP2480082A4 (en) * | 2009-09-25 | 2014-01-15 | Merck Sharp & Dohme | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES |
| TWI513695B (zh) * | 2009-10-27 | 2015-12-21 | Merck Sharp & Dohme | （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物 |
| EP2363825B1 (fr) | 2010-03-04 | 2016-04-27 | Inside Secure | Procédé pour conduire une transaction au moyen d'un dispositif NFC |
| JP2014513923A (ja) | 2011-03-04 | 2014-06-19 | ファイザー・インク | Ｅｄｎ３様ペプチドおよびその使用 |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| RU2615769C2 (ru) * | 2015-07-29 | 2017-04-11 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" | Средство для ингибирования фермента альфа-амилазы |
| US20220411372A1 (en) * | 2019-09-20 | 2022-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction |
| WO2024022521A1 (zh) * | 2022-07-28 | 2024-02-01 | 南通环聚泰生物科技有限公司 | 靶向BCL9/β-连环蛋白互相作用的小分子化合物 |
| WO2024145931A1 (zh) * | 2023-01-06 | 2024-07-11 | 上海医药工业研究院有限公司 | β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2025518A1 (es) * | 1969-06-05 | 1970-12-10 | ||
| US4476311A (en) * | 1980-03-12 | 1984-10-09 | The Purdue Frederick Company | Analgesic 4-carboxy-pyrrolidin-2-one compound |
| EP0077607A1 (en) * | 1981-09-17 | 1983-04-27 | Beecham Group Plc | N-substituted 3-aryl piperidines and derivatives thereof |
| EP0115607A1 (de) * | 1983-01-04 | 1984-08-15 | MERCK PATENT GmbH | Tetrahydrocarbazolderivate |
| GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5274143A (en) * | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| WO1993007141A1 (en) | 1991-10-11 | 1993-04-15 | Smithkline Beecham Corporation | Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production |
| WO1993012086A1 (en) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
| JPH05255089A (ja) * | 1991-12-18 | 1993-10-05 | Sanwa Kagaku Kenkyusho Co Ltd | 抗ウイルス剤 |
| JP3233991B2 (ja) * | 1992-06-26 | 2001-12-04 | 株式会社ソフィア | 遊技機 |
| ES2156120T3 (es) * | 1992-12-08 | 2001-06-16 | Ss Pharmaceutical Co | Derivados arilamidicos. |
| AU3138595A (en) | 1994-07-20 | 1996-02-16 | Acea Pharmaceuticals, Inc. | Haloperidol analogs and the use thereof |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JPH09312086A (ja) * | 1996-05-22 | 1997-12-02 | Matsushita Electric Ind Co Ltd | 光ディスク再生システム、光ディスク再生方法および光ディスク |
| EP0930882A2 (en) | 1996-08-02 | 1999-07-28 | Institut Pasteur De Lille | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
| IT1286497B1 (it) * | 1996-11-20 | 1998-07-15 | Italfarmaco Sud Spa | Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti |
| AU740733B2 (en) * | 1997-12-19 | 2001-11-15 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| DE69919436T2 (de) * | 1998-04-16 | 2005-09-15 | Pfizer Products Inc., Groton | N-Acyl und N-Aroyl Aralkylamide |
| US6376494B1 (en) * | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| GB9822473D0 (en) | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| US6303637B1 (en) * | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| CA2324330A1 (en) * | 1999-11-08 | 2001-05-08 | Ssp Co., Ltd. | 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same |
| US20020045613A1 (en) | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| WO2001085716A1 (en) | 2000-05-11 | 2001-11-15 | Kyowa Hakko Kogyo Co., Ltd | 2-piperidone compounds for the treatment of cancer |
| CA2409827C (en) | 2000-05-22 | 2010-06-01 | Aventis Pharmaceuticals Products Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
| AU2001211337A1 (en) | 2000-10-06 | 2002-04-15 | Smithkline Beecham Plc | Process for the preparation of aryl-piperidine carbinols and intermediates thereof |
| KR20030043970A (ko) | 2000-10-12 | 2003-06-02 | 에스에스 세야쿠 가부시키 가이샤 | 2,2-디페닐부탄아미드 유도체 및 이를 함유하는 의약 |
| JP2002173426A (ja) | 2000-12-05 | 2002-06-21 | Ss Pharmaceut Co Ltd | 血糖低下剤 |
| EP1361878A1 (en) * | 2001-02-15 | 2003-11-19 | Neurosearch A/S | Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity |
| MXPA03007284A (es) * | 2001-02-15 | 2003-12-04 | Pfizer Prod Inc | Agonistas de receptor activador del proliferador de peroxisomas. |
| WO2004048334A1 (en) * | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Phenyl substituted piperidine compounds for use as ppar activators |
-
2003
- 2003-11-14 WO PCT/IB2003/005235 patent/WO2004048334A1/en active Application Filing
- 2003-11-14 UA UAA200505008A patent/UA83202C2/ru unknown
- 2003-11-14 CN CNB200380104275XA patent/CN100439337C/zh not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005583A patent/MXPA05005583A/es active IP Right Grant
- 2003-11-14 SI SI200331552T patent/SI1567493T1/sl unknown
- 2003-11-14 PT PT03811832T patent/PT1567493E/pt unknown
- 2003-11-14 EA EA200500629A patent/EA008928B1/ru not_active IP Right Cessation
- 2003-11-14 DE DE60326752T patent/DE60326752D1/de not_active Expired - Lifetime
- 2003-11-14 CA CA002507465A patent/CA2507465C/en not_active Expired - Fee Related
- 2003-11-14 JP JP2004554809A patent/JP4029091B2/ja not_active Expired - Fee Related
- 2003-11-14 KR KR1020077012457A patent/KR100875318B1/ko not_active IP Right Cessation
- 2003-11-14 NZ NZ539546A patent/NZ539546A/en unknown
- 2003-11-14 BR BR0316521-3A patent/BR0316521A/pt not_active IP Right Cessation
- 2003-11-14 AT AT03811832T patent/ATE425966T1/de not_active IP Right Cessation
- 2003-11-14 KR KR1020057009389A patent/KR100760055B1/ko not_active IP Right Cessation
- 2003-11-14 PL PL378268A patent/PL378268A1/pl not_active Application Discontinuation
- 2003-11-14 EP EP03811832A patent/EP1567493B1/en not_active Expired - Lifetime
- 2003-11-14 AU AU2003276596A patent/AU2003276596B8/en not_active Ceased
- 2003-11-14 ES ES03811832T patent/ES2321509T3/es not_active Expired - Lifetime
- 2003-11-14 DK DK03811832T patent/DK1567493T3/da active
- 2003-11-24 AR ARP030104332A patent/AR042131A1/es unknown
- 2003-11-24 US US10/720,942 patent/US7199243B2/en not_active Expired - Fee Related
- 2003-11-25 PE PE2003001197A patent/PE20040699A1/es not_active Application Discontinuation
- 2003-11-25 TW TW092133036A patent/TW200424172A/zh unknown
- 2003-11-26 UY UY28097A patent/UY28097A1/es not_active Application Discontinuation
- 2003-11-26 GT GT200300258A patent/GT200300258A/es unknown
- 2003-11-26 NL NL1024881A patent/NL1024881C2/nl not_active IP Right Cessation
-
2005
- 2005-04-18 ZA ZA200503104A patent/ZA200503104B/en unknown
- 2005-04-20 IS IS7816A patent/IS7816A/is unknown
- 2005-05-16 HR HR20050437A patent/HRP20050437A2/hr not_active Application Discontinuation
- 2005-05-19 CO CO05048657A patent/CO5570701A2/es not_active Application Discontinuation
- 2005-05-26 TN TNP2005000146A patent/TNSN05146A1/fr unknown
- 2005-05-26 MA MA28299A patent/MA27532A1/fr unknown
- 2005-06-15 NO NO20052921A patent/NO20052921L/no not_active Application Discontinuation
-
2006
- 2006-03-20 HK HK06103485.0A patent/HK1083502A1/xx not_active IP Right Cessation
-
2007
- 2007-03-30 US US11/694,337 patent/US20070191429A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5570701A2 (es) | Activadores de ppar | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| AR038717A1 (es) | Ciclopropil-azol-carboxamidas | |
| CO5611113A2 (es) | Tripeptidos que poseen un eter de hidroxiprolina de una quinolina sustituida para la inhibicion de ns3 (hepatitis c) | |
| ES2126658T3 (es) | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. | |
| CO5690579A2 (es) | Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos | |
| CO5611131A2 (es) | Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa | |
| CO5611195A2 (es) | Novedosos inhibidores de la gamma secretasa | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| ECSP045243A (es) | Péptidos macrocíclicos activos contra el virus de la hepatitis C | |
| CO5700772A2 (es) | Composiciones de pirazole utiles como inhibidores de gsk-3 | |
| PE20050431A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
| CR9980A (es) | Imidazolinas 4,4,5,5 tetrasustituidas | |
| CO5611112A2 (es) | Tripeptidos inhibidores de la hepatitis c con absorcion oral mejorada y composiciones farmaceuticas que los contienen | |
| RS52978B (en) | FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS | |
| CO5290250A1 (es) | 1, 2, 3, 4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas | |
| CO4980897A1 (es) | De tipo 1 (nhe-1) utiles en el tratamiento de la isquemia | |
| CO6220972A2 (es) | Derivados de 6-amino dihidropurin -8-ona utiles como agentes terapeuticos y/o preventivos para el tratamiento de enfermedades alergicas, virales o cancer | |
| CO5550473A2 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformadors (tgf) | |
| CO5680450A2 (es) | Nuevo proceso para la preparacion de analogos de ciclosporina a | |
| ES2639065T3 (es) | Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos | |
| AR029145A1 (es) | Compuesto de hidroxamato pirrolidina sustituida, inhibidores de metaloproteasa, composicion farmaceutica que lo comprende y uso para elaborar una composicion farmaceutica | |
| AR074773A1 (es) | Piridazinonas sustituidas con fenilo en la posicion 4, su utilizacion como herbicidas e insecticidas en composiciones y metodos que los incluyen e intermediarios para su sintesis. | |
| AR061027A1 (es) | Inhibidores del virus del papiloma humano y las composiciones farmaceuticas que los contienen | |
| ECSP088294A (es) | Formulación en aerosol para la inhalación de beta-agonistas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |